Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update • Over 2 million total VOQUEZNA ® prescriptions filled through October 16, 2026 • Q3 2026 net revenues of $84.7 million increased 71% vs. Q3 2025 and 14% vs. Q2 2026 • G

Event · Earnings
Also in this documentGuidance · reaffirm · $310M–$325M

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 29, 2026, 11:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PHAT
Bullish
high confidence
Mentioned
$PHAT
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PHATBullishMed
01

Why it matters

The earnings beat and reaffirmed guidance may attract short‑term buying, while upcoming Phase 3 data could drive further moves.

02

Market read

Earnings beat and reaffirmed guidance provide a fresh catalyst for PHAT, likely prompting price appreciation.

03

What to watch

Potential regulatory risk around VOQUEZNA exclusivity litigation could temper upside.

Relevance 8/10Novelty 8/10Timing: after‑hours release on Oct 29
AlphAI · Earnings readPHAT · third quarter 2026 · ended September 30, 2026

Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

✓Solid quarter

Third-quarter net revenue increased 71% year over year and 14% sequentially, the company reported positive operating cash flow for the second consecutive quarter, GAAP net loss narrowed, and non-GAAP adjusted net income was positive. Full-year 2026 guidance was reaffirmed, although operating expenses increased and regulatory-exclusivity litigation remains unresolved.

Revenue
$84.7M
71% y/y · 14% q/q
EPS · non-GAAP
$ 0.04
FY 2026 Guidance outlook
$310–325 million
GM ~80%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Product revenue, net, three months ended September 30, 2026GAAP$84.72M14%71%
Cost of revenue, three months ended September 30, 2026GAAP18.37M––
Gross profit, three months ended September 30, 2026GAAP66.36M––
Research and development expenses, three months ended September 30, 2026GAAP$8.7M––
Selling, general and administrative expenses, three months ended September 30, 2026GAAP$57.7M––
Total operating expenses, three months ended September 30, 2026GAAP$66.4M––
Non-GAAP operating expenses excluding stock-based compensation, three months ended September 30, 2026non-GAAP$60.5M––
Loss from operations, three months ended September 30, 2026GAAP−85K––
Interest income, three months ended September 30, 2026GAAP1.6M––
Interest expense, three months ended September 30, 2026GAAP−15.39M––
Other expense, net, three months ended September 30, 2026GAAP−25K––
Total other expense, three months ended September 30, 2026GAAP−13.81M––
Net loss and comprehensive loss, three months ended September 30, 2026GAAP−$13.90M––
Net loss per share, basic and diluted, three months ended September 30, 2026GAAP$ (0.16)––
Non-GAAP adjusted net income (loss), three months ended September 30, 2026non-GAAP$2.99M––
Non-GAAP net income (loss) per share, basic and diluted, three months ended September 30, 2026non-GAAP$ 0.04––
Weighted-average shares of common stock outstanding, basic and diluted, three months ended September 30, 2026GAAP84,892,631––
Stock-based compensation, three months ended September 30, 2026other5.92M––
Product revenue, net, nine months ended September 30, 2026GAAP$217.3M––
Cost of revenue, nine months ended September 30, 2026GAAP45.46M––
Gross profit, nine months ended September 30, 2026GAAP171.8M––
Research and development expenses, nine months ended September 30, 2026GAAP24.33M––
Selling, general and administrative expenses, nine months ended September 30, 2026GAAP167.0M––
Total operating expenses, nine months ended September 30, 2026GAAP191.4M––
Loss from operations, nine months ended September 30, 2026GAAP−19.53M––
Net loss and comprehensive loss, nine months ended September 30, 2026GAAP−$61.85M––
Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP$ (0.74)––
Non-GAAP adjusted net income (loss), nine months ended September 30, 2026non-GAAP−$11.83M––
Non-GAAP net income (loss) per share, basic and diluted, nine months ended September 30, 2026non-GAAP$ (0.14)––
Cash and cash equivalents, September 30, 2026GAAP$184.6Man increase of $2.1 million–
Total assets, September 30, 2026GAAP$345.0M––
Total liabilities, September 30, 2026GAAP$692.7M––
Total stockholders' deficit, September 30, 2026GAAP−$347.6M––
VOQUEZNA prescriptions filled, third quarter 2026otherapproximately 380,000––
Covered VOQUEZNA prescriptions, third quarter 2026otherapproximately 248,000approximately 19%–
Cash-pay VOQUEZNA prescriptions, third quarter 2026other132,000approximately 6%–
Covered prescriptions as a percentage of total quarterly prescriptions, third quarter 2026otherapproximately 65%––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

FY 2026 Guidance outlook

  • Revenue$310–325 million
  • Gross margin~80%
  • Operating expenses$235–245 million, non-GAAP operating expenses, excluding stock-based compensation
  • NoteGross-to-net discount 55–59%

What drove it

  • Net-revenue growth was attributed to continued growth from execution of Phathom's commercial strategy.
  • Approximately 380,000 total VOQUEZNA prescriptions were filled during the third quarter 2026.
  • The company cited growing VOQUEZNA prescribing depth among GI providers and initiatives intended to improve physician prescribing and patient access.
  • Operating-expense growth reflected higher clinical development costs, commercial investment supporting the sales force and Access First initiatives, promotional costs, and personnel-related expenses.
  • The company introduced a new BlinkRx copay offering at the end of the third quarter under which eligible commercially insured patients may pay as little as $0 for VOQUEZNA.

Concerns

  • Total operating expenses increased to $66.4 million from $58.6 million in the prior-year period.
  • GAAP net loss remained $13.9 million and interest expense was $15.4 million for the third quarter 2026.
  • Total liabilities were $ 692,659 (in thousands) and total stockholders' deficit was $ (347,639) (in thousands) as of September 30, 2026.
  • BDR Pharmaceuticals and a second purported ANDA filer may succeed in challenging regulatory exclusivity, according to the company's risk disclosure.
  • The FDA public comment docket regarding issues raised in the exclusivity litigation has comments due November 23, 2026.

What to watch

  • Topline results from the 12-week blinded treatment portion of the Phase 2 pHalcon-EoE-201 trial are expected during the fourth quarter 2026.
  • Topline results from the pHalcon-NERD-302 registrational Phase 3 study are expected in the first quarter 2028.
  • The FDA public comment docket closes November 23, 2026, and the company intends to defend the regulatory exclusivity reflected in the Orange Book through May 3, 2032.
  • Execution against FY 2026 net revenue guidance of $310–325 million, gross-to-net discount guidance of 55–59%, gross-margin guidance of ~80%, and non-GAAP operating-expense guidance of $235–245 million, excluding stock-based compensation.

Balance sheet and cash flow

  • Cash and cash equivalents were $184.6 million as of September 30, 2026, an increase of $2.1 million compared to the second quarter ended June 30, 2026.
  • Phathom generated positive operating cash flow for the second consecutive quarter.
  • Total liabilities were $ 692,659 (in thousands) as of September 30, 2026.
  • Phathom stated that cash on hand and anticipated future cash generated from operations will be sufficient to invest in its business and satisfy all outstanding debt obligations without requiring additional debt or equity financing.

Analysis

Phathom reported third-quarter 2026 net revenue of $84.7 million, up 71% from $49.5 million in the third quarter of 2025 and up 14% from the second quarter of 2026. The company attributed the increase to continued execution of its commercial strategy. Commercial activity included approximately 380,000 VOQUEZNA prescriptions filled during the quarter, including approximately 248,000 covered prescriptions and 132,000 cash-pay prescriptions. Covered prescription volume increased approximately 19% sequentially, while cash-pay prescription volume increased approximately 6% sequentially.

Profitability improved materially from the prior-year quarter. Gross profit was 66,355 (in thousands), compared with 43,314 (in thousands), while loss from operations narrowed to 85 (in thousands) from 15,271 (in thousands). GAAP net loss narrowed to $13.9 million from $30.0 million. On a non-GAAP basis, adjusted net income was $3.0 million, compared with a non-GAAP adjusted net loss of $11.2 million. The non-GAAP measure excludes stock-based compensation, non-cash interest on the revenue interest financing liability, and interest expense related to amortization of debt discount on the term loan.

Expense discipline improved relative to the nine-month comparison, but quarterly spending increased. Third-quarter total operating expenses were $66.4 million versus $58.6 million in the prior-year period, driven by clinical-development and regulatory costs, promotional expense, personnel costs, and commercial investment. Non-GAAP operating expenses excluding stock-based compensation were $60.5 million, versus $49.3 million. Stock-based compensation declined to $5.9 million from $9.3 million. Interest expense remained substantial at 15,387 (in thousands) for the quarter.

Liquidity increased during the quarter. Cash and cash equivalents were $184.6 million at September 30, 2026, up $2.1 million versus June 30, 2026, and the company reported positive operating cash flow for the second consecutive quarter. The balance sheet also showed total liabilities of $ 692,659 (in thousands) and total stockholders' deficit of $ (347,639) (in thousands). Management stated that cash on hand and anticipated future cash generated from operations are expected to fund investment and satisfy outstanding debt obligations without additional debt or equity financing.

Phathom reaffirmed its FY 2026 guidance for net revenue of $310–325 million, gross-to-net discount of 55–59%, gross margin of ~80%, and non-GAAP operating expenses excluding stock-based compensation of $235–245 million. Operational catalysts include expected fourth-quarter 2026 topline results for the Phase 2 EoE trial and expected first-quarter 2028 results for the Phase 3 as-needed NERD study. The principal non-operating issue is the regulatory-exclusivity dispute: the company cites Orange Book NCE exclusivity through May 3, 2032, while litigation and an FDA public comment process remain ongoing.

Management, verbatim

We are pleased to report continued solid revenue growth and improved operating profitability for the third quarter.

Steve Basta, President and Chief Executive Officer of Phathom

We continue to grow VOQUEZNA prescribing depth among GI providers and have implemented several initiatives designed to make it easier for physicians to prescribe and patients to obtain our first-in-class GERD treatment.

Steve Basta, President and Chief Executive Officer of Phathom

Our third quarter results reflect Phathom’s significant financial transformation, with revenue growth of 71% year over year and positive cash flow from operations for the second consecutive quarter.

Sanjeev Narula, Chief Financial and Business Officer of Phathom

Not in the filing

stated, not guessed
  • Previous-release outlook was not provided, so no comparison with prior guidance is available.
  • GAAP gross margin for the third quarter 2026 was not reported.
  • A quantified operating cash flow amount was not reported.
  • Free cash flow was not reported.
  • Individual debt balances and debt maturities were not reported.
  • Capital returns, including share repurchases and dividends, were not reported.
  • A quantitative GAAP-to-non-GAAP reconciliation for FY 2026 guided operating expenses was not provided.
  • Prior-quarter values were not reported for most income-statement metrics.
  • No reportable revenue segments were disclosed.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Phathom Pharmaceuticals (Nasdaq: PHAT) filed an 8‑K reporting its third‑quarter 2026 results, highlighting revenue growth, cash‑flow positivity, and progress on its VOQUEZNA program.

Company-level read

Ticker impact

$PHATBullishHigh confidence
Context

Phathom Pharmaceuticals reported Q3 2026 net revenue of $84.7M, a 71% YoY increase, and reaffirmed full-year 2026 guidance.

Expected impact

likely upward pressure as investors price in strong revenue growth and positive cash flow

Evidence & confidence

The company delivered a material revenue increase, turned cash‑flow positive and reaffirmed guidance, which typically drives buying interest in biotech stocks.

Market effects

Strengthens outlook for GI‑focused biotech sector as VOQUEZNA gains market traction.

U.S. biotech investors may see modest rally.

Limited to niche GI therapeutic space.

Counterpoint

If Phase 3 data miss expectations, the stock could face sharp downside despite current earnings beat.

Key entities

  • Phathom Pharmaceuticals

    Biopharma developing VOQUEZNA for GERD and related GI indications.

Every PHAT earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$PHATMed

H.C. Wainwright reiterates Buy on Phathom stock, $26 target

H.C. Wainwright reiterated a Buy rating and $26 price target for Phathom Pharmaceuticals (PHAT), citing strong revenue growth and pipeline progress. The stock is up 8.36% weekly but down 62.5% year-to-date. Phathom reported Q3 2026 EPS of $0.04, beating estimates, but revenue missed slightly. The company is focused on VOQUEZNA's commercial execution and regulatory exclusivity.

$PHATMed

Phathom Pharmaceuticals Inc (PHAT) (Q3 2026) Earnings Call Highlights: Second

Phathom Pharmaceuticals (PHAT) reported stable commercial insurance coverage and no expected changes from a second PCAB entrant. Gross margin decline was due to a one-time manufacturing charge. Q4 revenue growth may reach the upper half of guidance due to momentum and Medicare Part D coverage. Phase 2 EOE trial data will be reported this quarter, with pediatric exclusivity discussions in 2027. 2027 revenue is expected to grow faster than operating expenses, driving positive cash flow.

$PHATMed

What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call

Phathom Pharmaceuticals (PHAT) reported Q3 gross profit margin of 78%, below guidance due to one-time charges. The company expects full-year 2026 gross-to-net discount toward the lower end of its 55%-59% range and maintains cash operating expense guidance of $235M-$245M. Phathom anticipates top-line data from its Phase II pHalcon-EoE study in Q4 and plans to discuss a Phase III program with the FDA in 2027 if results support further development.

$PHATMed

Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Phathom Pharmaceuticals reported Q3 2026 revenue of $84.7M, up 71% YoY, and maintained positive cash flow. The company launched 'Access First' to improve prescription adoption and introduced a $0 copay program. It reiterated FY2026 revenue guidance of $310M-$325M and expects durable positive cash flow in 2027. Phase II data for EoE is anticipated in Q4 2026.

$PHATMed

Phathom (PHAT) Q3 2026 Earnings Call Transcript

Phathom (PHAT) reported Q3 2026 net revenues of $84.7M, operating profit of $5.8M, and cash from operations of $2.1M. The company highlighted strong prescription growth for VOQUEZNA, with 2M+ prescriptions filled since launch. Phathom reiterated its full-year revenue guidance of $310M-$325M and discussed legal action by BDR Pharmaceuticals challenging VOQUEZNA's exclusivity period.